Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed133%
recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants

NCT05858502
terminated

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

NCT02487394
completed

sPLA2 in EBC During Acute Chest Syndrome

NCT03250585

Clinical Trials (3)

Showing 3 of 3 trials
NCT05858502Not Applicable

Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants

Recruiting
NCT02487394

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

Terminated
NCT03250585

sPLA2 in EBC During Acute Chest Syndrome

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3